New York, New York--(Newsfile Corp. - January 19, 2022) - Gainey McKenna & Egleston announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ: NRXP) (NASDAQ: NRXPW) in the United States District Court for the District of Delaware on behalf of investors who purchased NRx's common stock between June 1, 2021 and November 4, 2021, both dates inclusive (the "Class Period").
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (2) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times
Investors who purchased or otherwise acquired shares of NRx should contact the Firm prior to the March 21, 2022 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.
Please visit our website at http://www.gme-law.com for more information about the firm.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110835
